1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Mental Health Industry Analysis in European Union, August 2019

Mental Health Industry Analysis in European Union, August 2019

Customer Support

Talk to Veronica

+1 718 514 2762

All regions

data types

  • All
    • Industry Data
1-30 of 40 reports

Cymbalta

Cymbalta

  • $ 10000
  • Industry report
  • March 2019

Eli Lilly’s Cymbalta (duloxetine), a serotonin-norepinephrine reuptake inhibitor, was initially approved in the US in August 2004 for the treatment of major depressive disorder. The company has since ...

  • Industries : Pathology, Chronic Disease, Therapy, Mental Health
  • Countries : United States, Japan, European Union
Abilify/Abilify Maintena, Pharma Intelligence

Abilify/Abilify Maintena, Pharma Intelligence

  • $ 10000
  • Industry report
  • March 2019

Abilify (aripiprazole; Otsuka/Lundbeck) is an atypical antipsychotic that contains aripiprazole, a partial agonist of dopamine receptor D2 and serotonin receptor 5-HT1A, and antagonist of the 5-HT2A ...

  • Industries : Mental Health, Pathology
  • Countries : United States, Japan, European Union
Seroquel/Seroquel XR, Pharma Intelligence

Seroquel/Seroquel XR, Pharma Intelligence

  • $ 10000
  • Industry report
  • March 2019

The Seroquel franchise contains quetiapine, which acts as an antagonist at multiple neurotransmitter receptors in the brain, such as serotonin 5-HT1A and 5-HT2, dopamine D1 and D2, histamine H1, and adrenergic ...

  • Industries : Mental Health, Pathology
  • Countries : United States, European Union, Japan
Rexulti

Rexulti

  • $ 10000
  • Industry report
  • March 2019

Rexulti (brexpiprazole) is Otsuka’s latest atypical antipsychotic, approved simultaneously in the US for schizophrenia and major depressive disorder in July 2015. The drug acts similarly to Abilify (aripiprazole; ...

  • Industries : Mental Health, Pathology
  • Countries : United States, Japan, European Union
Global Spinal Muscular Atrophy Market: Industry Analysis & Outlook (2019-2026)

Global Spinal Muscular Atrophy Market: Industry Analysis & Outlook (2019-2026)

  • $ 800
  • Industry report
  • February 2019

Spinal Muscular Atrophy (SMA) is a form of neuromuscular disease that results in loss of lower motor neurons and progressive muscle wasting, often leading to early death.Presently, it affects about 1 in ...

  • Industries : Biopharmaceutical, Biopharmaceutical, Medical Biotechnology, Pharmaceutical, Mental Health
  • Countries : United States, World, European Union, North America
Alzheimer’s Disease Market and Forecast Analysis 2034

Alzheimer’s Disease Market and Forecast Analysis 2034

  • $ 22000
  • Industry report
  • February 2019

Disease OverviewAlzheimer’s disease is an irreversible, progressive, neurodegenerative, and fatal disease that slowly affects memory, cognition, and function. Alzheimer’s disease is the most common ...

  • Industries : Mental Health, Pathology
  • Countries : United States, Japan, European Union
Epilepsy Forecast and Market Analysis to 2035

Epilepsy Forecast and Market Analysis to 2035

  • $ 22000
  • Industry report
  • July 2018

DISEASE OVERVIEWEpilepsy is characterized by recurrent, unprovoked seizures. A seizure occurs when the normal pattern of neuronal activity is disturbed, defined by the National Institute of Neurological ...

  • Industries : Mental Health, Pathology
  • Countries : United States, European Union, Japan
Multiple Sclerosis Forecast and Market Analysis to 2025, Pharma Intelligence

Multiple Sclerosis Forecast and Market Analysis to 2025, Pharma Intelligence

  • $ 22000
  • Industry report
  • July 2018

DISEASE OVERVIEWMultiple sclerosis (MS) is an inflammatory, autoimmune disease characterized by neuronal demyelination leading to physical and cognitive disability. Although the etiology of MS is uncertain, ...

  • Industries : Mental Health, Pathology
  • Countries : United States, European Union, Japan
Parkinson’s disease forecast and market analysis to 2035

Parkinson’s disease forecast and market analysis to 2035

  • $ 22000
  • Industry report
  • June 2018

Disease OverviewParkinson’s disease is a chronic and progressive neurodegenerative disorder characterized by tremors, rigidity, bradykinesia (slowness of movement), and postural instability. Patients ...

  • Industries : Mental Health, Pathology
  • Countries : United States, European Union, Japan
Duopa

Duopa

  • $ 10000
  • Industry report
  • June 2018

Drug OverviewAbbVie’s Duopa, a continuous intestinal infusion of a carbidopa plus levodopa gel, is indicated for the treatment of advanced-stage idiopathic Parkinson’s disease with motor fluctuations ...

  • Industries : Mental Health, Pathology
  • Countries : United States, Japan, European Union
ND0612

ND0612

  • $ 10000
  • Industry report
  • June 2018

Drug OverviewThe ND0612 (Mitsubishi Tanabe) product line comprises two subcutaneous, continuously delivered carbidopa/levodopa liquid formulations: the lower-dose ND0612L, and the higher-dose ND0612H. ...

  • Industries : Mental Health, Pathology
  • Countries : United States, European Union
Azilect

Azilect

  • $ 10000
  • Industry report
  • June 2018

Drug OverviewAzilect (Teva/Lundbeck/Takeda) contains the pure R-isomer of rasagiline and acts as a selective irreversible monoamine oxidase inhibitor (MAOI), with up to 10 times more potency than selegiline ...

  • Industries : Mental Health, Pathology, Therapy
  • Countries : United States, Europe, Japan, European Union
Neupro

Neupro

  • $ 10000
  • Industry report
  • June 2018

Drug OverviewNeupro (UCB/Otsuka) is a transdermal formulation of the non-ergoline dopamine receptor agonist rotigotine. Applied once daily, the patch allows continuous drug administration over 24 hours ...

  • Industries : Mental Health, Pathology
  • Countries : United States, Japan, European Union
Inbrija

Inbrija

  • $ 10000
  • Industry report
  • June 2018

Drug OverviewInbrija (Acorda Therapeutics) is an inhaled formulation of levodopa, in development as an adjunct to existing oral levodopa formulations in patients experiencing motor fluctuations. Levodopa ...

  • Industries : Mental Health, Pathology
  • Countries : United States, European Union, Europe
Ongentys

Ongentys

  • $ 10000
  • Industry report
  • June 2018

Drug OverviewOngentys (Neurocrine/Bial/Ono Pharmaceutical) is a once-daily formulation of the catechol-O-methyltransferase (COMT) inhibitor opicapone, approved as an add-on therapy to levodopa for the ...

  • Industries : Mental Health, Pathology
  • Countries : United States, Japan, European Union, North America
Abilify/Abilify Maintena

Abilify/Abilify Maintena

  • $ 10000
  • Industry report
  • April 2018

Drug Overview Abilify (aripiprazole; Otsuka/Lundbeck) is an atypical antipsychotic that contains aripiprazole, a partial agonist of dopamine receptor D2 and serotonin receptor 5-HT1A, and antagonist of ...

  • Industries : Mental Health, Pathology
  • Countries : United States, European Union, Japan
Drug Overview: Zyprexa

Drug Overview: Zyprexa

  • $ 10000
  • Industry report
  • April 2018

Drug OverviewZyprexa (Eli Lilly) contains the atypical antipsychotic olanzapine, which acts as an antagonist at the D2 and 5-HT2A receptors. Zyprexa was initially launched in September 1996 for the treatment ...

  • Industries : Mental Health, Pathology
  • Countries : United States, Japan, European Union
Drug Overview: Risperdal Consta

Drug Overview: Risperdal Consta

  • $ 10000
  • Industry report
  • April 2018

Drug Overview Risperdal Consta (Johnson&Johnson) contains risperidone, an atypical antipsychotic that acts as a selective dopamine and serotonin receptor antagonist that also blocks the dopamine D2, serotonin ...

  • Industries : Mental Health, Pathology
  • Countries : United States, European Union, Japan
Bipolar Disorder Disease Coverage to 2024

Bipolar Disorder Disease Coverage to 2024

  • $ 22000
  • Industry report
  • April 2018

Disease Overview Bipolar disorder is a psychiatric disorder characterized by unusual shifts in mood, energy, activity levels, and the ability to carry out everyday tasks. Patients with the disorder may ...

  • Industries : Mental Health, Pathology, Therapy
  • Countries : United States, Japan, European Union
Seroquel/Seroquel XR

Seroquel/Seroquel XR

  • $ 10000
  • Industry report
  • April 2018

Drug Overview The Seroquel franchise contains quetiapine, which acts as an antagonist at multiple neurotransmitter receptors in the brain, such as serotonin 5-HT1A and 5-HT2, dopamine D1 and D2, histamine ...

  • Industries : Mental Health, Pathology
  • Countries : United States, Japan, European Union
Drug Overview: Vraylar

Drug Overview: Vraylar

  • $ 10000
  • Industry report
  • April 2018

Drug Overview Vraylar (cariprazine; Gedeon Richter/Allergan/Mitsubishi Tanabe) is a novel atypical antipsychotic with partial agonistic activity at D2 and D3 receptors, and selectivity for the D3 receptor. ...

  • Industries : Mental Health, Pathology
  • Countries : United States, European Union
Drug Overview: Latuda

Drug Overview: Latuda

  • $ 10000
  • Industry report
  • April 2018

Drug Overview Latuda (lurasidone; Sumitomo Dainippon/Angelini) contains the atypical antipsychotic lurasidone, which acts as an antagonist of dopamine receptors D2, and serotonin receptors 5-HT2A. By ...

  • Industries : Mental Health, Pathology
  • Countries : United Kingdom, Italy, Japan, European Union, United States, Germany, Spain
Drug Overview: Rexulti

Drug Overview: Rexulti

  • $ 10000
  • Industry report
  • April 2018

Drug Overview Rexulti (brexpiprazole) is Otsuka’s latest atypical antipsychotic, approved simultaneously in the US for schizophrenia and major depressive disorder in July 2015. The drug acts similarly ...

  • Industries : Mental Health, Pathology
  • Countries : United States, Japan, European Union
Drug Overview: Nuplazid

Drug Overview: Nuplazid

  • $ 10000
  • Industry report
  • March 2018

Drug Overview Nuplazid (Acadia Pharmaceuticals) contains pimavanserin, which is a selective serotonin inverse agonist preferentially targeting the serotonin 5-HT2A receptors. Its novel mechanism of action ...

  • Industries : Therapy, Mental Health
  • Countries : United States, European Union
Drug Overview: Invega Sustenna/Invega Trinza

Drug Overview: Invega Sustenna/Invega Trinza

  • $ 10000
  • Industry report
  • March 2018

Drug Overview Invega Sustenna and Invega Trinza (paliperidone palmitate; Johnson&Johnson) are long-acting injectable formulations developed by Johnson&Johnson, using with Alkermes’s technology. The ...

  • Industries : Mental Health, Pathology, Therapy
  • Countries : United States, European Union, Japan
Schizophrenia Disease Coverage to 2024

Schizophrenia Disease Coverage to 2024

  • $ 22000
  • Industry report
  • March 2018

Schizophrenia is a serious mental illness, characterized by incoherent or illogical thoughts, bizarre behavior and speech, and delusions or hallucinations, such as hearing voices. Schizophrenia typically ...

  • Industries : Mental Health, Pathology
  • Countries : United States, Japan, European Union
Multiple Sclerosis Forecast and Market Analysis to 2025

Multiple Sclerosis Forecast and Market Analysis to 2025

  • $ 22000
  • Industry report
  • November 2017

DISEASE OVERVIEWMultiple sclerosis (MS) is an inflammatory, autoimmune disease characterized by neuronal demyelination leading to physical and cognitive disability. Although the etiology of MS is uncertain, ...

  • Industries : Mental Health, Pathology
  • Countries : European Union, United States, Japan
Drug Analysis: Copaxone

Drug Analysis: Copaxone

  • $ 10000
  • Industry report
  • November 2017

Drug OverviewCopaxone is an immunomodulator composed of four amino acids found in myelin basic protein, believed to act by modifying immune processes in the pathogenesis of MS. It was the third disease-modifying ...

  • Industries : Mental Health
  • Countries : United States, Japan, European Union
Drug Anaylsis: Gilenya

Drug Anaylsis: Gilenya

  • $ 10000
  • Industry report
  • November 2017

Drug OverviewGilenya is a synthetic derivative of ISP-1 (myriocin), a fungal metabolite of the Chinese herb isaria sinclarii which acts as a potent agonist at four of the S1P receptors (S1P1, S1P3, S1P4, ...

  • Industries : Mental Health
  • Countries : United States, Japan, European Union
Drug Analysis: ALKS 8700

Drug Analysis: ALKS 8700

  • $ 10000
  • Industry report
  • November 2017

Drug OverviewALKS 8700 is an oral monomethyl fumarate molecule being developed for the treatment of relapsing multiple sclerosis. Alkermes designed this drug to have Tecfidera-like efficacy, but to also ...

  • Industries : Drug Development
  • Countries : United States, European Union

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on